

8. The method of claim 6, wherein the antibody is administered by the route selected from the group consisting of intramuscularly, intravenously, intradermally, cutaneously, ionophoretically, topically, locally, and inhalation.

9. The method of claim 6, wherein the antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a synthetic antibody, a heavy chain antibody and a humanized antibody.

10. The heavy chain antibody of claim 9, wherein the heavy chain antibody is selected from the group consisting of a camelid antibody, a heavy chain disease antibody, and a variable heavy chain immunoglobulin.

In the Specification

Please amend the specification as follows:

On page 1 of the specification, after the Title of the Invention and before the Background of the Invention, please insert the following paragraph.

CROSS-REFERENCE TO RELATED APPLICATIONS

--This application is a continuation of U.S. Application No. 10/422,119, filed April 24, 2003, which is hereby incorporated herein by reference in its entirety.--

REMARKS

The present invention includes a method of treating schizophrenia in a mammal comprising administering to the mammal a composition comprising antibody to tumor necrosis factor alpha.

Support for the instant claims can be found throughout the specification and as detailed more fully herein.

Support for treating schizophrenia can be found at, for example, page 18, beginning at line 4, and at page 44, beginning at line 16.